| Name | Title | Contact Details |
|---|
Continental Generals mission is to assist our customers with managing the financial risks and challenges that come as they age. Our skills, resources, and infrastructure allow us to help them with insulating and enhancing retirement income and maneuvering caregiving options. Thus allowing us to responsibly be a part of the solution rather than the problem. Our team of long-term care industry experts, with headquarters in Austin, Texas, strives to build value through superior operating results. As we manage our current portfolio of business, we continue to pursue growth opportunities for expansion and economies of scale through strategic acquisitions, mergers, and reinsurance opportunities. Our family of insurance companies and strategic partners provide administrative services to approximately 125,000 Long-Term Care, Life, Annuity and Supplemental Health customers. We are dedicated to upholding the commitments we have made to provide excellent service to all our customers and serve the needs of our claimants and their families during difficult times.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Axolight is a lighting company, based in Italy and the United States, which designs and produces high-end decorative design lamps. Handmade in Italy Each Axolight product, whether it derives from mass production or from a customized request, is designed, developed, tested and assembled by hand at the company workshop in Venice - Scorzè.
World Athletics is the international governing body for athletics (track & field & running events). Our vision is to use the power and accessibility of athletics and our athletes to create a healthier and fitter world. World Athletics serves a number of stakeholders: professional athletes, their coaches, and their agents, and the 214 national athletics federations that make up the organisation, commercial partners and broadcasters. We work closely with the local organising committees to stage the biggest athletics events all over the world, to excite and engage with fans of all ages.
BNCCORP, Inc. (OTCQB: BNCC), headquartered in Bismarck, N.D., is a registered bank holding company dedicated to providing banking and wealth management services to businesses and consumers in its local markets. The Company operates community banking and wealth management businesses in Arizona, Minnesota and North Dakota. BNC also conducts mortgage banking from locations in the Midwest. The Company offers financial products and services to meet the financial needs of its current customers, and potential customers, in the markets it serves.